Stock Price Movements, Presentation Schedules, and Quarterly Dividends -
Research Report on Biogen Idec, Santarus, Hill-Rom, Puma Biotechnology and
Editor Note: For more information about this release, please scroll to bottom
NEW YORK, November 29, 2013
NEW YORK, November 29, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Biogen
Idec Inc. (NASDAQ: BIIB), Santarus, Inc. (NASDAQ: SNTS), Hill-Rom Holdings,
Inc. (NYSE: HRC), Puma Biotechnology, Inc. (NYSE: PBYI), and Cynosure, Inc.
(NASDAQ: CYNO). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
Biogen Idec Inc. Research Report
On November 25, 2013, Biogen Idec Inc. (Biogen Idec) announced that it will
present at the 2013 Deutsche Bank BioFEST on December 3, 2013 at 10:45 a.m.
E.T. Biogen Idec informed that the live webcast of the presentation and its
archive (available for 14 days) may be accessed through the investor's section
of the Company's website. In other news dated November 22, 2013, Biogen Idec
announced that the Committee for Medicinal Products for Human Use (CHMP) of
the European Medicines Agency (EMA) has determined that dimethyl fumarate in
TECFIDERA qualifies as a new active substance (NAS). The Company informed that
this designation will provide regulatory exclusivity for TECFIDERA for 10
years in the European Union (EU). Douglas Williams, Ph.D., Executive Vice
President of Research and Development at Biogen Idec said, "We are heartened
by the CHMP's NAS determination, which brings us closer to our goal of
providing this important new treatment to multiple sclerosis (MS) patients in
Europe. We are ready to introduce TECFIDERA in EU countries shortly after
anticipated approval. This designation validates the tremendous investment we
have made in TECFIDERA and enables us to invest in future research focused on
reversing the course of MS and hopefully one day finding a cure for patients."
The Full Research Report on Biogen Idec Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:
Santarus, Inc. Research Report
On November 26, 2013, Santarus, Inc.'s (Santarus) stock closed at $32.09, down
0.06%. However, the Company's stock was up by 0.38% over the past three
trading day period, compared to the Dow Jones Industrial Average which was up
by 0.39% during the same three trading day period. The Full Research Report on
Santarus, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
Hill-Rom Holdings, Inc. Research Report
On November 20, 2013, Hill-Rom Holdings, Inc.'s (Hill-Rom) announced that the
Company's Board of Directors has declared a cash dividend of c.$0.14 per share
for Q1 FY 2014. The Company stated that the said dividend is payable on
December 27, 2013, to shareholders of record as of the close of business on
December 13, 2013. According to Hill-Rom, the declared quarterly cash
dividend reflects a 10% YoY increase and brings the dividends paid per share
over the last 12 months to c.$0.54. In another release dated November 19,
2013, Hill-Rom announced that the Company will present at the 25th Annual
Piper Jaffray Healthcare Conference on December 3, 2013, at 9:30 a.m. E.S.T.
The Company informed that the live audio of the presentation will be available
at the events section under the Company's investor relations website.
Hill-Room added that a recorded replay of the discussion will be available one
hour after the conclusion of the event and will be accessible at the same
place until December 17, 2013.The Full Research Report on Hill-Rom Holdings,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
Puma Biotechnology, Inc. Research Report
On November 26, 2013, Puma Biotechnology, Inc.'s (Puma Biotechnology) stock
was up by 1.99%, closing the day at $49.25. For the past three trading days,
the Company stock went up significantly by 9.32%, compared to the S&P 500
which went up by 0.38% during the same trading period. The Full Research
Report on Puma Biotechnology, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
Cynosure, Inc. Research Report
On November 26, 2013, Cynosure, Inc.'s (Cynosure) stock went up by 0.87%,
closing the day at $24.29. However, the Company's stock went down by 1.38%
over the previous three trading sessions, compared to the Nasdaq Composite
which went up by 1.22% during the same trading period. The Full Research
Report on Cynosure, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
1.This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
are only human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
4.If you wish to have your company covered in more detail by our team, or
wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
SOURCE Analysts' Corner
Contact: Joe Thomas; +1-310-496-8071 (North America)
Press spacebar to pause and continue. Press esc to stop.